TNK2 (Tyrosine Kinase Non-Receptor 2)
A non-receptor tyrosine kinase involved in cell growth, migration, and cancer progression.
Gene Information Card
| Symbol | TNK2 |
|---|---|
| Full Name | Tyrosine Kinase Non-Receptor 2 |
| Gene Type | protein-coding |
| Chromosomal Location | 3q29 |
| NCBI Gene ID | 10188 ncbi.nlm.nih.gov/gene/10188 |
| Ensembl ID | ENSG00000161960 |
| UniProt ID | Q07912 |
| OMIM ID | 606994 |
| HGNC ID | 11971 |
| Aliases | ACK1, ACK, p21cdc42Hs |
Description
TNK2 (Tyrosine Kinase Non-Receptor 2), also known as ACK1, encodes a non-receptor tyrosine kinase that binds to and is activated by CDC42. It plays a role in cell growth, migration, and survival by phosphorylating various substrates, including AKT and EGFR. TNK2 is implicated in several cancers and other diseases.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Prostate cancer | TNK2 overexpression and amplification lead to increased AKT signaling and tumor progression. | PMID: 16959974 |
| Breast cancer | TNK2 amplification and mutation contribute to oncogenic signaling and poor prognosis. | PMID: 20010872 |
| Lung cancer | TNK2 overexpression promotes cell proliferation and invasion via EGFR pathway activation. | PMID: 23541953 |
| Glioblastoma | TNK2 mutations and altered expression are associated with tumor growth and resistance to therapy. | PMID: 24120142 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Brain | 12.5 | Medium |
| Lung | 8.3 | Low |
| Liver | 6.1 | Low |
| Kidney | 9.7 | Low |
| Testis | 15.2 | Medium |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HEK 293 | 14.0 | Embryonic kidney cells |
| HeLa | 11.5 | Cervical cancer cells |
| A549 | 9.8 | Lung cancer cells |
| MCF7 | 13.2 | Breast cancer cells |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.2114A>G (p.Tyr705Cys) | Missense | <0.01% | Unknown functional impact |
| c.2260G>A (p.Gly754Arg) | Missense | <0.01% | Potential gain-of-function in cancer |
| c.1234C>T (p.Arg412Trp) | Missense | <0.01% | Reported in glioblastoma |
Mutation functional classification
Loss of Function (LOF)
No well-characterized loss-of-function mutations reported.
Gain of Function (GOF)
Mutations such as p.Gly754Arg may enhance kinase activity and promote oncogenic signaling.
Dominant Negative (DN)
Not described for TNK2.
View complete mutation data：
Gene Ontology (GO)
Pathways
• EGFR tyrosine kinase inhibitor resistance (KEGG: hsa01521)
• Signaling by Receptor Tyrosine Kinases (Reactome: R-HSA-9006934)
• PI3K-Akt signaling pathway (KEGG: hsa04151)
Protein Summary
TNK2 encodes a 1036-amino acid non-receptor tyrosine kinase with an N-terminal tyrosine kinase domain, a SH3 domain, and a C-terminal CDC42-binding domain. It is activated by CDC42 and phosphorylates substrates such as AKT, EGFR, and WASP, regulating cell proliferation, migration, and survival. The protein is overexpressed or mutated in various cancers.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| TNK2 Knockout HEK293 Cell Line | EDJ-KQ6952 | Human | 10188 | Details Get a Quote |
| ETNK2 Knockout HEK293 Cell Line | EDJ-KQ13336 | Human | 55224 | Details Get a Quote |
| TNK2 Knockout A-549 Cell Line | EDJ-KQ31622 | Human | 10188 | Details Get a Quote |
| TNK2 Knockout HCT 116 Cell Line | EDJ-KQ31623 | Human | 10188 | Details Get a Quote |
| TNK2 Knockout HeLa Cell Line | EDJ-KQ31624 | Human | 10188 | Details Get a Quote |
| ETNK2 Knockout A-549 Cell Line | EDJ-KQ42809 | Human | 55224 | Details Get a Quote |
| ETNK2 Knockout HCT 116 Cell Line | EDJ-KQ42810 | Human | 55224 | Details Get a Quote |
| ETNK2 Knockout HeLa Cell Line | EDJ-KQ42811 | Human | 55224 | Details Get a Quote |
Displaying Records 1 To 8 Of 8 Records
